Point-of-care testing of coagulation in patients treated with non-Vitamin K antagonist oral anticoagulants

Stroke

Volumn 46, Issue 10, 2015, Pages 2741-2747

  Ebner, Matthias ^a   Peter, Andreas ^b   Spencer, Charlotte ^a   Härtig, Florian ^a   Birschmann, Ingvild ^c   Kuhn, Joachim ^c   Wolf, Martin ^a   Winter, Natalie ^a   Russo, Francesca ^a   Zuern, Christine S ^b   Blumenstock, Gunnar ^b   Ziemann, Ulf ^a   Poli, Sven ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Apixaban; Dabigatran; Rivaroxaban; Stroke; Thrombolytic therapy

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING TEST; BRAIN ISCHEMIA; CLINICAL TRIAL; COAGULOMETER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; SECONDARY PREVENTION; TANDEM MASS SPECTROMETRY; THROMBOEMBOLISM; AGED; BLOOD; FEMALE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; DABIGATRAN; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; POINT-OF-CARE TESTING; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE;

EID: 84942867498     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.010148     Document Type: Article

References (26)

1. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Effcacy and safety of the novel oral anticoagulants in atrial fbrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381-2391. doi: 10.1161/CIRCULATIONAHA.112.115410.
2. Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixa-ban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013;102:399-412. doi: 10.1007/s00392-013-0560-7.
3. Tripodi A. The laboratory and the direct oral anticoagulants. Blood. 2013;121:4032-4035. doi: 10.1182/blood-2012-12-453076.
4. Kitchen S, Gray E, Mackie I, Baglin T, Makris M; BCSH committee. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol. 2014;166:830-841. doi: 10.1111/bjh.12975.
5. Rizos T, Herweh C, Jenetzky E, Lichy C, Ringleb PA, Hacke W, et al. Point-of-care international normalized ratio testing accelerates throm-bolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke. 2009;40:3547-3551. doi: 10.1161/STROKEAHA.109.562769.
6. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012;125:417-420. doi: 10.1016/j.amjmed.2011.10.017.
7. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11:1493-1502. doi: 10.1111/jth.12308.
8. Eller T, Busse J, Dittrich M, Flieder T, Alban S, Knabbe C, et al. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin Chem Lab Med. 2014;52:835-844. doi: 10.1515/cclm-2013-0936.
9. Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost. 2014;111:1133-1140. doi: 10.1160/TH13-10-0871.
10. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815-825. doi: 10.1160/TH09-03-0176.
11. Mani H, Herth N, Kasper A, Wendt T, Schuettfort G, Weil Y, et al. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit. 2014;36:624-631. doi: 10.1097/FTD.0000000000000064.
12. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fbrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50:675-686. doi: 10.2165/11595320-000000000-00000.
13. European Medicines Agency. Eliquis, INN-apixaban: summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/002148/WC500107728. pdf. Accessed February 5, 2015.
14. European Medicines Agency. Pradaxa, INN-dabigatran: summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000829/WC500041059.pdf. Accessed February 10, 2015.
15. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012;126:2428-2432. doi: 10.1161/CIRCULATIONAHA.112.123224.
16. European Medicines Agency. Xarelto, INN-rivaroxaban: summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000944/WC500057108.pdf. Accessed February 10, 2015.
17. Vassarstats: Website for Statistical Computation. http://vassarstats.net/clin1.html. Accessed February 5, 2014.
18. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64:1128-1139. doi: 10.1016/j.jacc.2014.05.065.
19. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fbrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-2104. doi: 10.1161/CIR.0000000000000040.
20. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947. doi: 10.1161/STR.0b013e318284056a.
21. Douxfls J, Tamigniau A, Chatelain B, Goffnet C, Dogné JM, Mullier F. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J. 2014;12:24. doi: 10.1186/1477-9560-12-24.
22. Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, et al. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. Intern Med J. 2014;44:525-536. doi: 10.1111/imj.12448.
23. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J. 2013;34:489-498b. doi: 10.1093/eurheartj/ehs408.
24. Diener HC, Foerch C, Riess H, Röther J, Schroth G, Weber R. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment. Lancet Neurol. 2013;12:677-688. doi: 10.1016/S1474-4422(13)70101-7.
25. Grotta JC, Hacke W. Stroke neurologist's perspective on the new endo-vascular trials. Stroke. 2015;46:1447-1452. doi: 10.1161/STROKEAHA. 115.008384.
26. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9:133-139. doi: 10.1111/j.1538-7836.2010.04098.x.